New York State Common Retirement Fund Has $6.27 Million Stake in Pacira Pharmaceuticals, Inc. (PCRX)

New York State Common Retirement Fund decreased its stake in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 1.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 166,934 shares of the company’s stock after selling 3,105 shares during the period. New York State Common Retirement Fund owned approximately 0.41% of Pacira Pharmaceuticals worth $6,268,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Pacira Pharmaceuticals by 9.2% in the second quarter. BlackRock Inc. now owns 3,478,281 shares of the company’s stock worth $165,914,000 after acquiring an additional 294,494 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Pacira Pharmaceuticals by 7.4% in the second quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock worth $146,538,000 after acquiring an additional 211,982 shares in the last quarter. HealthCor Management L.P. lifted its stake in shares of Pacira Pharmaceuticals by 63.1% in the second quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock worth $85,564,000 after acquiring an additional 693,799 shares in the last quarter. State Street Corp lifted its stake in shares of Pacira Pharmaceuticals by 1.0% in the second quarter. State Street Corp now owns 1,118,083 shares of the company’s stock worth $53,340,000 after acquiring an additional 10,727 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its stake in shares of Pacira Pharmaceuticals by 1.6% in the second quarter. Macquarie Group Ltd. now owns 1,091,530 shares of the company’s stock worth $52,066,000 after acquiring an additional 16,760 shares in the last quarter.

In related news, CAO Kristen Marie Williams sold 10,000 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 23,455 shares of the company’s stock, valued at approximately $938,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP James B. Jones sold 850 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $41.11, for a total value of $34,943.50. The disclosure for this sale can be found here. Insiders sold a total of 70,075 shares of company stock valued at $2,707,452 over the last three months. Corporate insiders own 6.60% of the company’s stock.

Several analysts have issued reports on PCRX shares. Jefferies Group cut their price objective on Pacira Pharmaceuticals to $52.00 and set a “buy” rating on the stock in a research note on Thursday, November 9th. Canaccord Genuity set a $42.00 price objective on Pacira Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, November 29th. Piper Jaffray Companies restated a “buy” rating and set a $55.00 price objective on shares of Pacira Pharmaceuticals in a research note on Friday, October 27th. Wedbush restated an “outperform” rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, October 25th. Finally, BidaskClub cut Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $48.73.

Pacira Pharmaceuticals, Inc. (PCRX) opened at $44.15 on Friday. The company has a market capitalization of $1,820.00, a P/E ratio of -33.70 and a beta of 2.20. Pacira Pharmaceuticals, Inc. has a fifty-two week low of $29.81 and a fifty-two week high of $58.95. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The company had revenue of $67.30 million during the quarter, compared to analyst estimates of $68.99 million. During the same period in the prior year, the company earned $0.20 earnings per share. The business’s revenue was down 1.6% compared to the same quarter last year. sell-side analysts predict that Pacira Pharmaceuticals, Inc. will post -0.85 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “New York State Common Retirement Fund Has $6.27 Million Stake in Pacira Pharmaceuticals, Inc. (PCRX)” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/24/new-york-state-common-retirement-fund-has-6-27-million-stake-in-pacira-pharmaceuticals-inc-pcrx.html.

Pacira Pharmaceuticals Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

What are top analysts saying about Pacira Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pacira Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit